CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a strategic partnership with Waters Corporation, a global leader in life sciences and diagnostics, creating a framework to jointly pursue companion diagnostic (CDx) and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies.
The collaboration will initially emphasise flow cytometry-based programmes. For CDx opportunities, the partnership aims to provide sponsors with a coordinated path from biomarker strategy through clinical development, regulatory submission and global commercialisation.
The complementary expertise of CellCarta and Waters spans assay innovation, development, validation, and global implementation. Waters provides underlying technology capabilities, including instrumentation, reagents, standardised panels, assay development, software analysis, and, where appropriate, custom reagent and IVD commercialisation.
CellCarta leverages its extensive biomarker, translational research, and clinical development expertise to integrate and deploy the assay across its global CDx Lab Network, supporting Phase 1-3 clinical trial testing, generation of analytical and clinical evidence, regulatory and logistics support, and commercial laboratory services. Together, the companies aim to deliver standardised and globally scalable solutions for precision medicine.
The existing platform alignment between CellCarta’s CAP-accredited laboratory’s capabilities in Jining, China and BD flow cytometry platforms create a practical foundation for global sponsors seeking to include China in future multinational CDx and biomarker programmes, as well as China-based biopharmaceutical companies preparing to expand their therapies and diagnostic strategies globally.
